Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07860411
Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis With Nasal Polyps
An observational study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Nasal Polyps, run by Harran University at 1 site in Turkey (Türkiye).
Trial summary
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the sinonasal mucosa whose metabolic and immunologic mechanisms are incompletely understood. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Nasal Polyps
- What is being tested?
- Nasal polyp tissue and blood sampling and Nasal mucosa and blood sampling
- How many people
- 80 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Mar 2026to 10 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult patients presenting with nasal obstruction to the Otorhinolaryngology outpatient clinic of Harran University Faculty of Medicine, Şanlıurfa, Turkey, with histopathologically confirmed chronic rhinosinusitis with nasal polyps (by punch biopsy or surgical specimen), and adult control patients without chronic rhinosinusitis scheduled for septoplasty, rhinoplasty or similar nasal surgery at the same department.
Who may be able to join
- Age 18 years or older
- Diagnosis of chronic rhinosinusitis with nasal polyps at the Otorhinolaryngology outpatient clinic
- Diagnosis of nasal polyposis confirmed by histopathological examination of a punch biopsy or surgical specimen
- No condition preventing the collection of tissue and peripheral blood samples within the scope of the study
- Age 18 years or older
- No history of nasal polyposis or chronic rhinosinusitis
- Scheduled for septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps
- Collection of a healthy nasal mucosa biopsy during surgery poses no additional risk
Who cannot join
- Acute upper respiratory tract infection or acute rhinosinusitis
- History of systemic inflammatory or autoimmune disease
- History of malignancy or active malignant disease
- Immunodeficiency or use of immunosuppressive therapy
- Use of systemic corticosteroids, biologic agents or immunomodulatory therapy within the last 4 weeks
- Use of antibiotics for an acute infection within the last 4 weeks
Show all 10Show fewer
- Pregnancy or breastfeeding
- Presence of an additional systemic disease severe enough to prevent participation in the study
- Control Group
- Same exclusion criteria as the CRSwNP group
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Harran University Faculty of Medicine Hospital, Department of Otorhinolaryngology
Sanliurfa, Şanlıurfa, 63300
Mahmut Ağırtmış, MD, +905012392163, mahmutagirtmis@harran.edu.tr
About this study
Official title: Investigation of Metabolic and Immunological Biomarkers in Tissue and Peripheral Blood of Patients With Chronic Rhinosinusitis With Nasal Polyposis
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the sinonasal mucosa whose metabolic and immunologic mechanisms are incompletely understood. This prospective case-control study aims to characterize metabolic and immunologic biomarkers in patients with CRSwNP compared with control subjects. Nasal tissue and peripheral blood samples will be analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for free amino acid and carnitine/acylcarnitine profiles, and levels of interleukin-40 (IL-40), interleukin-6 (IL-6), and hypoxia-inducible factor-1 alpha (HIF-1α) will be measured by ELISA. The findings are expected to contribute to understanding disease pathogenesis and to identifying potential diagnostic biomarkers and therapeutic targets.
Read the detailed description
Adult patients presenting to the Otorhinolaryngology outpatient clinic of Harran University Faculty of Medicine with nasal obstruction and a histopathologically confirmed diagnosis of nasal polyposis (by punch biopsy or surgical specimen) will be enrolled. Nasal polyp tissue and peripheral blood samples will be collected from 40 patients with CRSwNP. The control group will consist of 40 patients undergoing septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps, from whom healthy nasal mucosa biopsies and peripheral blood samples will be obtained. Free amino acid and carnitine/acylcarnitine profiles will be determined in tissue and serum by LC-MS/MS, and IL-40, IL-6 and HIF-1α concentrations will be measured by ELISA. Metabolic and immunologic differences between nasal polyp tissue and healthy nasal mucosa, and their reflection in peripheral blood, will be compared between groups. Tissue and blood levels obtained from the same individual will be compared using paired tests, and correlations between metabolic parameters and immune markers will be assessed by Pearson or Spearman correlation analysis. In the CRSwNP group, associations of these biomarkers with disease severity, symptom scores and endoscopic findings will also be evaluated. The diagnostic performance of candidate biomarkers will be assessed by receiver operating characteristic (ROC) analysis. To our knowledge, IL-40 has not previously been investigated in CRSwNP.
- Being tested
- Nasal polyp tissue and blood sampling, Nasal mucosa and blood sampling
- Keywords
- Metabolomics, LC-MS/MS, Interleukin-40, Interleukin-6, HIF-1 alpha, Biomarkers, Amino acids, Acylcarnitines
- Medical subject headings
- Nasal Polyps
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nasal polyp tissue and blood samplingOther
Nasal polyp tissue is obtained by punch biopsy in the outpatient clinic or during endoscopic sinus surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.
Nasal mucosa and blood samplingOther
A healthy nasal mucosa biopsy is obtained during septoplasty, rhinoplasty or similar nasal surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.
| Study group | Role | What they receive |
|---|---|---|
| CRSwNP Group | Adult patients diagnosed with chronic rhinosinusitis with nasal polyps according to EPOS 2020 criteria, with nasal polyposis confirmed histopathologically by punch biopsy or surgical specimen. Nasal polyp tissue is obtained by punch biopsy in the outpatient clinic or during endoscopic sinus surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied. Receives: Other: Nasal polyp tissue and blood sampling | |
| Control Group | Adult patients without nasal polyposis or chronic rhinosinusitis scheduled for septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps. A healthy nasal mucosa biopsy is obtained during surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied. Receives: Other: Nasal mucosa and blood sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tissue and serum free amino acid and carnitine/acylcarnitine profiles
Concentrations of free amino acids, free carnitine and acylcarnitines measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in nasal tissue and serum, compared between the CRSwNP and control groups.
Measured: At the time of tissue sampling (Day 0)
Interleukin-40 (IL-40) levels in tissue and serum
IL-40 concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.
Measured: At the time of tissue sampling (Day 0)
Secondary outcomes (3)
Interleukin-6 (IL-6) levels in tissue and serum
IL-6 concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.
Measured: At the time of tissue sampling (Day 0)
Hypoxia-inducible factor-1 alpha (HIF-1α) levels in tissue and serum
HIF-1α concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.
Measured: At the time of tissue sampling (Day 0)
Diagnostic performance of candidate biomarkers
Area under the receiver operating characteristic curve (AUC), sensitivity and specificity of tissue and serum amino acid, carnitine/acylcarnitine, IL-40, IL-6 and HIF-1α levels for discriminating CRSwNP from control subjects.
Measured: At the time of tissue sampling (Day 0)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2026
- Study start15 Mar 2026
- Primary completion15 Dec 2026 (estimated)
- Study completion10 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Harran University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Servet Erdemes, Harran University
- Investigators
- Servet Erdemes, MD, Principal investigator, Harran UniversityMahmut Ağırtmış, MD, Study director, Harran University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07860411
- Sponsor's protocol ID
- HRÜ26.03.14
- Other IDs
- 26092
- Status last verified
- Oct 2026
- First submitted
- 1 Oct 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared in order to protect participant confidentiality in accordance with national personal data protection regulations (KVKK).
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Metabolic and Immunological Biomarkers in Tissue and Peripheral Blood of Patients With Chronic Rhinosinusitis With Nasal Polyposis
- ClinicalTrials.gov ID
- NCT07860411
- Acronym / sponsor ID
- HRÜ26.03.14
- Keywords
- Metabolomics, LC-MS/MS, Interleukin-40, Interleukin-6, HIF-1 alpha, Biomarkers, Amino acids, Acylcarnitines
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Harran UniversityUniversity, hospital or other
- Study start
- 15 Mar 2026 (actual)
- Primary completion
- 15 Dec 2026 (estimated)
- Study completion
- 10 Mar 2027 (estimated)
- First posted
- 6 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the sinonasal mucosa whose metabolic and immunologic mechanisms are incompletely understood. This prospective case-control study aims to characterize metabolic and immunologic biomarkers in patients with CRSwNP compared with control subjects. Nasal tissue and peripheral blood samples will be analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for free amino acid and carnitine/acylcarnitine profiles, and levels of interleukin-40 (IL-40), interleukin-6 (IL-6), and hypoxia-inducible factor-1 alpha (HIF-1α) will be measured by ELISA. The findings are expected to contribute to understanding disease pathogenesis and to identifying potential diagnostic biomarkers and therapeutic targets.
Detailed description
Adult patients presenting to the Otorhinolaryngology outpatient clinic of Harran University Faculty of Medicine with nasal obstruction and a histopathologically confirmed diagnosis of nasal polyposis (by punch biopsy or surgical specimen) will be enrolled. Nasal polyp tissue and peripheral blood samples will be collected from 40 patients with CRSwNP. The control group will consist of 40 patients undergoing septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps, from whom healthy nasal mucosa biopsies and peripheral blood samples will be obtained. Free amino acid and carnitine/acylcarnitine profiles will be determined in tissue and serum by LC-MS/MS, and IL-40, IL-6 and HIF-1α concentrations will be measured by ELISA. Metabolic and immunologic differences between nasal polyp tissue and healthy nasal mucosa, and their reflection in peripheral blood, will be compared between groups. Tissue and blood levels obtained from the same individual will be compared using paired tests, and correlations between metabolic parameters and immune markers will be assessed by Pearson or Spearman correlation analysis. In the CRSwNP group, associations of these biomarkers with disease severity, symptom scores and endoscopic findings will also be evaluated. The diagnostic performance of candidate biomarkers will be assessed by receiver operating characteristic (ROC) analysis. To our knowledge, IL-40 has not previously been investigated in CRSwNP.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CRSwNP Group | – | Other: Nasal polyp tissue and blood samplingAdult patients diagnosed with chronic rhinosinusitis with nasal polyps according to EPOS 2020 criteria, with nasal polyposis confirmed histopathologically by punch biopsy or surgical specimen. Nasal polyp tissue is obtained by punch biopsy in the outpatient clinic or during endoscopic sinus surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied. |
| Control Group | – | Other: Nasal mucosa and blood samplingAdult patients without nasal polyposis or chronic rhinosinusitis scheduled for septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps. A healthy nasal mucosa biopsy is obtained during surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients presenting with nasal obstruction to the Otorhinolaryngology outpatient clinic of Harran University Faculty of Medicine, Şanlıurfa, Turkey, with histopathologically confirmed chronic rhinosinusitis with nasal polyps (by punch biopsy or surgical specimen), and adult control patients without chronic rhinosinusitis scheduled for septoplasty, rhinoplasty or similar nasal surgery at the same department.
Key inclusion criteria (8 listed)
- Age 18 years or older
- Diagnosis of chronic rhinosinusitis with nasal polyps at the Otorhinolaryngology outpatient clinic
- Diagnosis of nasal polyposis confirmed by histopathological examination of a punch biopsy or surgical specimen
- No condition preventing the collection of tissue and peripheral blood samples within the scope of the study
- Age 18 years or older
Key exclusion criteria (10 listed)
- Acute upper respiratory tract infection or acute rhinosinusitis
- History of systemic inflammatory or autoimmune disease
- History of malignancy or active malignant disease
- Immunodeficiency or use of immunosuppressive therapy
- Use of systemic corticosteroids, biologic agents or immunomodulatory therapy within the last 4 weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nasal polyp tissue and blood samplingNasal polyp tissue is obtained by punch biopsy in the outpatient clinic or during endoscopic sinus surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied. | Other | CRSwNP Group |
| Nasal mucosa and blood samplingA healthy nasal mucosa biopsy is obtained during septoplasty, rhinoplasty or similar nasal surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied. | Other | Control Group |
Primary outcome
Tissue and serum free amino acid and carnitine/acylcarnitine profiles
Time frame: At the time of tissue sampling (Day 0)
Concentrations of free amino acids, free carnitine and acylcarnitines measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in nasal tissue and serum, compared between the CRSwNP and control groups.
Interleukin-40 (IL-40) levels in tissue and serum
Time frame: At the time of tissue sampling (Day 0)
IL-40 concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.
3 secondary outcomes
Interleukin-6 (IL-6) levels in tissue and serum
Time frame: At the time of tissue sampling (Day 0)
Hypoxia-inducible factor-1 alpha (HIF-1α) levels in tissue and serum
Time frame: At the time of tissue sampling (Day 0)
Diagnostic performance of candidate biomarkers
Time frame: At the time of tissue sampling (Day 0)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared in order to protect participant confidentiality in accordance with national personal data protection regulations (KVKK).
Related trials for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
RecruitingObservational study
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
RecruitingPhase 3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
RecruitingObservational study
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Asthma
Not yet recruitingObservational study
Neural Dissimilarity in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Biologics
Olfactory Dysfunction, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Not yet recruitingObservational study
China CRSwNP Registry Study
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Servet Erdemes, MD principal investigator
Harran University
Mahmut Ağırtmış, MD study director
Harran University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Nasal Polyps, run by Harran University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mahmut Ağırtmış, MD (+905012392163, mahmutagirtmis@harran.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tissue and serum free amino acid and carnitine/acylcarnitine profiles (time frame: At the time of tissue sampling (Day 0)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.